
Rodovita provides digital patient twins and AI-powered therapies for personalized, regenerative medicine. It operates as a Biotech 4.0 platform with lab and clinical modules and a digital backbone for LIS, CMMS, ERP, and future digital twin capabilities that connect R&D, clinical practice and industry partners. Key technologies include AI, digital twins, organoids-on-a-chip, 3D bioprinting, NFT-powered biomaterial certification, and blockchain security. The system functions as an integrated bio-digital factory, combining automated laboratory processes, organoid testing, and AI-based treatment forecasting. The company targets patients and health providers seeking transparent, scalable, personalized treatments in modern healthcare.

Rodovita provides digital patient twins and AI-powered therapies for personalized, regenerative medicine. It operates as a Biotech 4.0 platform with lab and clinical modules and a digital backbone for LIS, CMMS, ERP, and future digital twin capabilities that connect R&D, clinical practice and industry partners. Key technologies include AI, digital twins, organoids-on-a-chip, 3D bioprinting, NFT-powered biomaterial certification, and blockchain security. The system functions as an integrated bio-digital factory, combining automated laboratory processes, organoid testing, and AI-based treatment forecasting. The company targets patients and health providers seeking transparent, scalable, personalized treatments in modern healthcare.